Cargando…
An Overview on Different L-Thyroxine (l-T(4)) Formulations and Factors Potentially Influencing the Treatment of Congenital Hypothyroidism During the First 3 Years of Life
Congenital hypothyroidism (CH) is a relatively frequent congenital endocrine disorder, caused by defective production of thyroid hormones (THs) at birth. Because THs are essential for the development of normal neuronal networks, CH is also a common preventable cause of irreversible intellectual disa...
Autores principales: | Stagi, Stefano, Municchi, Giovanna, Ferrari, Marta, Wasniewska, Malgorzata Gabriela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218053/ https://www.ncbi.nlm.nih.gov/pubmed/35757415 http://dx.doi.org/10.3389/fendo.2022.859487 |
Ejemplares similares
-
Comparison Among Two Liquid Formulations of L-thyroxine in the Treatment of Congenital Hypothyroidism in the First Month of Life: A Pilot Study
por: Tuli, Gerdi, et al.
Publicado: (2022) -
l-Thyroxine in an Oral Liquid or Softgel Formulation Ensures More Normal Serum Levels of Free T4 in Patients with Central Hypothyroidism
por: Benvenga, Salvatore, et al.
Publicado: (2017) -
Thyroxine Treatment With Softgel Capsule Formulation: Usefulness in Hypothyroid Patients Without Malabsorption
por: Trimboli, Pierpaolo, et al.
Publicado: (2018) -
MON-081 Mathematical Modeling of Residual Endogenous FT4 Synthesis and Exogenous L-Thyroxine Administration over the First 2 Years of Life in Infants with Congenital Hypothyroidism
por: Leroux, Stéphanie, et al.
Publicado: (2020) -
MON-102 Serum Concentrations of FT4 and TSH in the First Six Months of L-Thyroxine Treatment in Infants with Congenital Hypothyroidism: Target Attainment Rates Should Be Improved
por: Leroux, Stéphanie, et al.
Publicado: (2020)